MMW - Fortschritte der Medizin

, Volume 156, Issue 9, pp 41–46 | Cite as

Das geht an die Nieren!

Schlechte Blutzuckereinstellung bei Diabetes mellitus
  • Christiane Drechsler
  • Andreas Schneider
  • Kay-Renke Schmidt
  • Christoph Wanner
FORTBILDUNG_SCHWERPUNKT
  • 31 Downloads

Zusammenfassung

Die diabetesassoziierte Nephropathie (DNP) ist eine direkte Folgeerkrankung der diabetischen Stoffwechselstörung, die zu einer Angiopathie der Kapillaren des Nierenkörperchens (Glomerulum) führt. Aber nicht alle Diabetiker sind betroffen. Lesen Sie, wer besonders gefährdet ist und was Sie tun können.

Keywords - The diabetic patient with nephropathy

Diabetic nephropathy HbA1c glomerular filtration rate – antidiabetic treatment kidney disease 

Literatur

  1. 1.
    Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 1989;4(10):859–863Google Scholar
  2. 2.
    Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes–Langfassung, 1. Auflage. Version 2. 2013, zuletzt geändert: September 2013. Available from: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_Therapie; DOI: 10.6101/AZQ/000170.
  3. 3.
    Hasslacher C et al. Nephropathie bei Diabetes. Diabetologie 2013;8:S119–S122CrossRefGoogle Scholar
  4. 4.
    de Zeeuw D, Akizawa T, Audhya Pet al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. The New England journal of medicine. Dec 26 2013;369(26):2492–2503.PubMedCrossRefGoogle Scholar
  5. 5.
    Parving HH, Brenner BM, McMurray JJet al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. The New England journal of medicine 2012;367(23):2204–2213PubMedCrossRefGoogle Scholar
  6. 6.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England journal of medicine 2004;351(13):1296–1305PubMedCrossRefGoogle Scholar
  7. 7.
    Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney international 2003;63(4): 1468–1474PubMedCrossRefGoogle Scholar
  8. 8.
    van der Velde M, Matsushita K, Coresh J et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney international 2011; 79(12):1341–1352.PubMedCrossRefGoogle Scholar
  9. 9.
    Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of internal medicine 2001;134(8):629–636PubMedCrossRefGoogle Scholar
  10. 10.
    Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. CJASN 2007;2(6):1306–1316PubMedGoogle Scholar
  11. 12.
    Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Annals of internal medicine 2013;158(11):825–830PubMedCrossRefGoogle Scholar
  12. 12.
    Wada J, Makino H. Clinical Science 2013;124: 139–152PubMedCrossRefGoogle Scholar
  13. 13.
    Fioretto P, Mauer M. Semin Nephrol 2007; 27(2):195–207PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–1625PubMedCrossRefGoogle Scholar
  15. 15.
    Tervaert TW, Mooyaart AL, Amann K et al. Pathologic classification of diabetic nephropathy. JASN 2010;21(4):556–563.PubMedCrossRefGoogle Scholar
  16. 16.
    Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870–878PubMedCrossRefGoogle Scholar
  17. 17.
    Drury PL, Smith GM Ferriss JB. Increased vasopressor responsiveness to aniotensin II in type 1 (insulin-dependent) diabetic patients without complications. Diabetologia 1984;27:174–179.PubMedGoogle Scholar
  18. 18.
    Hollenberg NK, Price DA, Fisher NDet al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney international 2003;63(1):172–178PubMedCrossRefGoogle Scholar
  19. 19.
    Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. JASN 2005; 16(4):1135–1140PubMedCrossRefGoogle Scholar
  20. 20.
    Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. The Cochrane database of systematic reviews 2010(4):CD002967.Google Scholar
  21. 21.
    Ekstrom N, Schioler L, Svensson AMet al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ open 2012;2(4)Google Scholar
  22. 22.
    Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes care 2011; 34(6):1431–1437PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
  24. 24.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977–986Google Scholar
  25. 25.
    Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes care 1999; 22(1):99–111Google Scholar
  26. 26.
    DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;22;365(25):2366–2376Google Scholar
  27. 27.
    Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861–869PubMedCrossRefGoogle Scholar
  28. 28.
    Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851–860PubMedCrossRefGoogle Scholar
  29. 29.
    Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15): 1547–1559PubMedCrossRefGoogle Scholar
  30. 30.
    Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369(20):1892–1903PubMedCrossRefGoogle Scholar
  31. 31.
    2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of hypertension 2013;31(10):1925–1938Google Scholar
  32. 32.
    KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney international 2014Google Scholar
  33. 33.
    Locatelli F, Barany P, Covic Aet al. Kidney Disease. Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. European Renal Association 2013;28 (6):1346–1359Google Scholar

Copyright information

© Urban & Vogel 2014

Authors and Affiliations

  • Christiane Drechsler
    • 1
  • Andreas Schneider
    • 1
  • Kay-Renke Schmidt
    • 1
  • Christoph Wanner
    • 1
  1. 1.Medizinische Klinik und Poliklinik I, Schwerpunkt NephrologieUniversitätsklinik WürzburgWürzburgDeutschland

Personalised recommendations